Jeff Legos, PhD, MBA

Board of Governors

Chief Oncology Officer, Pfizer

Jeff Legos, PhD, MBA is Executive Vice President and Chief Oncology Officer at Pfizer, where he is responsible for leading the company’s Oncology Research & Development, overseeing all functions from discovery to late-stage clinical development activities and medical affairs. Pfizer Oncology is focused on delivering transformative therapies in some of the world’s most common cancers: breast cancer, across hormonal subtypes; genitourinary cancer, including prostate and bladder cancer; hematologic malignancies, and thoracic cancers, which includes lung cancer. With an industry-leading portfolio and extensive pipeline utilizing three core modalities to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and non-ADC biologics, Pfizer Oncology is at the forefront of a new era in cancer care.

Before joining Pfizer in May 2025, Dr. Legos served as Executive Vice President and Global Head of Oncology and Hematology Development at Novartis, where he was responsible for a clinical pipeline of 45+ low molecular weight small molecules, advanced biotherapeutics, radioligand, cell & gene therapies, and established product assets across a broad range of cancers and blood disorders. Prior to this, Dr. Legos served as Vice President and Global Medicines Development Leader in Oncology at GlaxoSmithKline (GSK), where he also held other senior leadership positions in clinical development and translational medicine. During his tenure, Dr. Legos was instrumental in the creation and growth of the GSK Oncology Business Unit. Dr. Legos has a proven track record of successfully leading large multinational teams across all functions and stages of drug development for more than 20 years, which has resulted in more than 40 global drug and companion diagnostic regulatory approvals, including new molecular entities, product line extensions, and premarket approvals for devices.

Dr. Legos earned his PhD in physiology from Temple University School of Medicine, an MBA in Finance from the Villanova University School of Business and completed his post-graduate fellowship training in pharmacology and pharmaceutical medicine. Dr. Legos is an author of more than 50 manuscripts and numerous abstracts published in peer-reviewed journals and serves as a scientific advisor to the Melanoma Research Alliance, a Strategic Advisory Board member for Gingko Bioworks, and represented Novartis as key expert advisor on several industry-wide Oncology Task Forces for Friends of Cancer Research, LUNGevity, and Bloomberg New Economy.